Emmanuel Ligner, group executive, Danaher Biotechnology Group—who is also president and CEO of Cytiva—said the expansion will enable that company and Pall to meet demand for manufacturing across modalities that monoclonal antibodies, recombinant protein, and cell and gene therapy; as well as production basics used in the making of cells such as chromatography resins, cell culture media, and single-use technologies . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge